Literature DB >> 2069391

SCH 39304 in the treatment of acute or established murine pulmonary blastomycosis.

E Brummer1, L H Hanson, D A Stevens.   

Abstract

SCH 39304 was tested for treatment of acute or established murine pulmonary blastomycosis and was compared with ketoconazole and fluconazole in a model of acute infection. Only SCH 39304 at 25 or 50 mg/kg of body weight per day produced 100% survival for 30 days after the 20-day treatment, although only 33% of the mice were cleared of infection. SCH 39304 at 2 mg/kg/day was similar to ketoconazole at 100 mg/kg/day and to fluconazole at 10 mg/kg/day. In a model of established blastomycosis, used to evaluate long-term treatment of very sick or moribund mice, SCH 39304 at 50 mg/kg/day protected against death with a 96% cumulative 8-week survival. SCH 39304 was clearly superior on a milligram-per-kilogram basis in acute blastomycosis, and long-term treatment of more severe blastomycosis was curative.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2069391      PMCID: PMC245103          DOI: 10.1128/AAC.35.4.788

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Blastomycosis.

Authors:  G A Sarosi; S F Davies
Journal:  Am Rev Respir Dis       Date:  1979-10

2.  Comparison of fluconazole and ketoconazole in experimental murine blastomycosis.

Authors:  D A Stevens; E Brummer; J G McEwen; A M Perlman
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

3.  Efficacy of itraconazole in blastomycosis in a murine model and comparison with ketoconazole.

Authors:  E G Arathoon; E Brummer; D A Stevens
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

4.  Virulence of fungi: correlation of virulence of Blastomyces dermatitidis in vivo with escape from macrophage inhibition of replication in vitro.

Authors:  E Brummer; P A Morozumi; D E Philpott; D A Stevens
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

5.  Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.

Authors:  A M Sugar; M Picard; L Noble
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

Authors:  W E Dismukes; A M Stamm; J R Graybill; P C Craven; D A Stevens; R L Stiller; G A Sarosi; G Medoff; C R Gregg; H A Gallis; B T Fields; R L Marier; T A Kerkering; L G Kaplowitz; G Cloud; C Bowles; S Shadomy
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

7.  Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis.

Authors:  K V Clemons; L H Hanson; A M Perlman; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis.

Authors:  R M Tucker; L H Hanson; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters.

Authors:  R P Harvey; E S Schmid; C C Carrington; D A Stevens
Journal:  Am Rev Respir Dis       Date:  1978-04

10.  Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

Authors:  J N Galgiani; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

View more
  2 in total

Review 1.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

2.  Activities of the triazole D0870 in vitro and against murine blastomycosis.

Authors:  K V Clemons; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.